RONALD WAUTERS: Open Payments
NPI 1801854195 · SEARCY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,296 in 122 payments from 14 companies in 2025. Trend: 2023 $44,507 · 2024 $4,222 · 2025 $2,296
Food & beverage: $2,184Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $467 |
| Teva Pharmaceuticals USA, Inc. | 15 | $314 |
| Otsuka America Pharmaceutical, Inc. | 14 | $244 |
| Neurocrine BioSciences, Inc. | 10 | $223 |
| E.R. Squibb & Sons, L.L.C. | 13 | $220 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $198 |
| Janssen Pharmaceuticals, Inc | 9 | $166 |
| Lundbeck LLC | 9 | $138 |
| Axsome Therapeutics, Inc. | 6 | $121 |
| Supernus Pharmaceuticals, Inc. | 3 | $76 |
Products named: VRAYLAR, INGREZZA, COBENFY, REXULTI, CAPLYTA, UZEDY, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across AR — which companies pay providers there.
